LICENSE AGREEMENTLicense Agreement • December 12th, 2022 • Oculis Holding AG • Pharmaceutical preparations
This LICENSE AGREEMENT (collectively with all Appendices hereto, “Agreement”) is entered into as of January 29, 2022 (“Effective Date”), by and between:
LICENSE AGREEMENT by and between ALCON RESEARCH, LTD. and OCULIS SA, dated 19 December, 2018License Agreement • December 12th, 2022 • Oculis Holding AG • Pharmaceutical preparations
This LICENSE AGREEMENT (this “Agreement”) is made as of this 19th day of December, 2018 (the “Execution Date”), by and between Alcon Research, Ltd., a company organized under the laws of the State of Delaware and located at 6201 South Freeway, Fort Worth, Texas USA 76134-2099 (“Alcon”) and Oculis SA, a company organized under the laws of Switzerland and located at EPFL Innovation Park, c/o Building C, 1015 Lausanne, Switzerland (“Oculis”). Alcon and Oculis are each referred to individually as a “Party” and together as the “Parties.”
LETTER AGREEMENT By and between NOVARTIS TECHNOLOGY LLC and OCULIS SA October 12, 2021Oculis Holding AG • December 12th, 2022 • Pharmaceutical preparations
Novartis Technology LLC (“Novartis”), located at One Health Plaza, East Hanover, New Jersey 07936 United States (as successor to Alcon Research Ltd), and Oculis SA (“Company”) are the Parties to a certain License Agreement dated December 19, 2018, as amended on September 11, 2020 (the “Agreement”). This Letter Agreement clarifies and modifies certain terms of the Agreement with the aim of [***]. Capitalized terms not otherwise defined in this letter have the meanings set forth in the Agreement. The following terms apply notwithstanding anything contrary in the Agreement.
AMENDMENTOculis Holding AG • December 12th, 2022 • Pharmaceutical preparations
